Rapid progression of chronic myelomonocytic leukemia following diaminodiphenyl sulphone treatment for dermatitis herpetiformis

International Journal of Hematology

Volumn 66, Issue 3, 1997, Pages 383-385

  Kanda, Yoshinobu ^a   Chiba, Shigeru ^a   Hirano, Naoto ^a   Hirai, Hisamaru ^a   Yazaki, Yoshio ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Chronic myelomonocytic leukemia; Dermatitis herpetiformis; Diaminodiphenyl sulphone; Diaminodiphenyl sulphone syndrome

Indexed keywords

DAPSONE;

ADULT; ARTICLE; BONE MARROW BIOPSY; CASE REPORT; CHRONIC MYELOMONOCYTIC LEUKEMIA; DERMATITIS HERPETIFORMIS; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKOCYTE COUNT; MALE; NEUTROPENIA; PRIORITY JOURNAL; SEPTIC SHOCK;

EID: 0031259523     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0925-5710(97)00041-8     Document Type: Article

References (5)

1. Allday E.J., Barnes J. Toxic effects of diaminodiphenyl sulphone in treatment of leprosy. Lancet. 2:1951;205-206.
2. Swerdlow A.J., Whittaker S., Carpenter L.M., English J.S.C. Mortality and cancer incidence in patients with dermatitis herpetiformis: A cohort study. Br J Dermatol. 129:1993;140-144.
3. Bennett J.M., Catovsky D., Daniel M.T.et al. Proposals for the classification of the myelodysplastic syndromes. Br J Heamatol. 51:1982;189-199.
4. Frey H.M., Gershon A.A., Borkowsky W., Bullock W.E. Fatal reaction to dapsone during treatment of leprosy. Ann Intern Med. 94:1981;777-779.
5. Levine P.H., Weintraub L.R. Pseudoleukemia during recovery from dapson-induced agranulocytosis. Ann Intern Med. 68:1968;1060-1065.